Medicare Coverage Changes for Weight-Loss Drugs: What You Need to Know
Upcoming changes to Medicare's coverage of weight-loss drugs could significantly impact healthcare providers starting in July. The new program will allow eligible Medicare seniors access to GLP-1 medications such as Wegovy, previously unavailable to them, at a monthly copay of $50. This development is expected to drive high demand from the approximately 14 million overweight or obese Medicare beneficiaries, as estimated by KFF.
Christopher Weber, a board member of the Obesity Medicine Association, highlighted concerns over an expected surge in patients seeking treatment, who had previously been unable to afford these medications. He noted to Axios that this influx could overwhelm clinics already handling extensive prior authorization requests, potentially delaying care.
The procedure for obtaining coverage includes a prior authorization stage, crucial for verifying patient eligibility for these discounted drugs. Physicians are also expressing concerns about the essential patient management required with GLP-1 medications, which involves close monitoring of dosages and managing side effects such as nausea, vomiting, and excessive weight loss—particularly critical for older adults facing increased risks of frailty.
The Medicare GLP-1 Bridge Program, as announced by the Centers for Medicare & Medicaid Services, will continue providing these benefits until the end of 2027. However, it does not encompass necessary nutritional and behavioral support, prompting worries regarding the adequacy of care for achieving sustainable and secure weight loss in seniors.
Financial considerations persist despite discounts. According to Juliette Cubanski of KFF, patients might find that the $50 copay does not contribute to their deductibles or out-of-pocket maximums. Additionally, certain beneficiaries already receiving GLP-1 treatments under other Medicare plans might be deemed ineligible for the new program.
The program's launch coincides with escalating healthcare sector costs, with Mercer data projecting a 9% increase in prescription drug benefits by 2026, partly driven by costly GLP-1 therapies. Some insurers are reacting by restricting access, with several large employers planning to reduce or limit GLP-1 medication coverage by 2026.
This policy shift presents substantial market opportunities for pharmaceutical companies like Novo Nordisk A/S and Eli Lilly and Co., positioned to capitalize on the increased demand among Medicare recipients.